Study of fatty liver cirrhosis prevention strategies
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests strategies to prevent cirrhosis in people with metabolic fatty liver disease and early to moderate liver scarring. It aims to find better ways to stop liver damage from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with metabolic fatty liver disease (MAFLD).
- You have had a liver biopsy in the last 6 months that shows early to moderate fibrosis (stage F0-F4).
- You do not have cirrhosis caused by other liver diseases like hepatitis B or C.
- You have no history of serious liver complications (fluid in belly, bleeding varices, or confusion).
- You have not had heavy drinking episodes in the past year, and have not used certain liver-harming medications for more than 2 weeks in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medication called Chiglitazar (a type of insulin sensitizer) is safe and effective for people with cirrhosis caused by metabolic-associated fatty liver disease (MAFLD). It may help reduce liver scarring and improve metabolic health.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
This study looks at how a specific gut bacteria (Ruminococcus gnavus) and its byproducts are linked to fatty liver disease (MAFLD). It compares people with the condition to healthy individuals to better understand the connection.
This trial tests whether Fuzheng Huayu tablets can help people with fatty liver disease that has progressed to cirrhosis (scarring) that is still compensated (the liver is still working well). The goal is to see if the tablets slow or reverse liver damage.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.